TCR2 Therapeutics Inc. believes that its technology platform for the development of T-cell receptor (TCR)-based therapies can make the cancer treatments available to more patients, including people with solid tumors, and now it has $125m to take at least two candidates into the clinic.
Cambridge, Mass.-based TCR2 announced March 21 that it closed a Series B venture capital round to pursue clinical proof-of-concept for...